WASHINGTON, July 2, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of Entasis TherapeuticsInc. (Entasis) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. Entasis utilizes a unique pathogen-targeted approach to develop a robust clinical and pre-clinical pipeline of potential
The new addition brings AWG's membership to 18 antimicrobial drug and diagnostic device development companies.
"AWG looks forward to working with Entasis Therapeutics, the newest member of our coalition, to advance our mission to improve the regulatory, investment and commercial environment for antimicrobial drug and diagnostic device development," said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara Therapeutics and Chairman of AWG. "Entasis is a leader in the fight against AMR, discovering and developing novel antibacterials to address the serious medical need posed by multi-drug resistant bacterial infections, helping to provide doctors and patients with the innovative infectious disease treatment options, and is a valuable addition to the group."
"Entasis Therapeutics is proud to partner with the AWG in its efforts to improve the investment and commercial landscape for antimicrobials," said Manos Perros, CEO of Entasis Therapeutics. "The response to the growing medical need of antimicrobial resistance requires a concerted effort to ensure that patients infected by drug-resistant pathogens have access to safe and effective targeted therapies. We look forward to contributing to the AWG's important policy initiatives required to incentivize the development and facilitate the integration of such novel therapies into the commercial environment."
All pharmaceutical and biotechnology companies developing new antimicrobial therapeutics and diagnostic devices are eligible for consideration of membership in AWG. If you are interested in learning more about becoming a member of AWG, please contact us here.
About Entasis Therapeutics Inc.
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' targeted-design platform has produced a pipeline of product candidates, including ETX2514SUL (targeting A. baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), and zoliflodacin (targeting Neisseria gonorrhoeae). Entasis is also using its platform to develop a novel class of non-?-lactam penicillin-binding protein inhibitors (NBPs) targeting Gram-negative infections.
For more information, visit www.entasistx.com
About The Antimicrobials Working Group
AWG was founded in 2012 with the vision of utilizing collective power to improve the regulatory, investment, and commercial environment for emerging infectious disease companies. Today, AWG is comprised of eighteen antimicrobials and diagnostics companies: Amplyx Pharmaceuticals, Aridis Pharmaceuticals, Arsanis Inc., Cidara Therapeutics Inc., ContraFect Corporation, Entasis Therapeutics Inc., Iterum Therapeutics Ltd., Melinta Therapeutics Inc., Motif Bio PLC, Nabriva Therapeutics US Inc., Paratek Pharmaceuticals Inc., SCYNEXIS Inc., Spero Therapeutics, Inc., T2 Biosystems Inc., Theravance Biopharma U.S. Inc., Viamet, Vical Incorporated, and Zavante Therapeutics Inc.
For more information, visit: www.antimicrobialsworkinggroup.org
About The Conafay Group
The Conafay Group, led by Stephen R. Conafay, Principal, is a life-sciences government relations firm based in Washington D.C. that serves as Washington counsel and coalition manager for AWG.
For more information, visit: www.conafaygroup.com
View original content:http://www.prnewswire.com/news-releases/entasis-therapeutics-inc-joins-antimicrobials-working-group-300674670.html
SOURCE The Conafay Group; Antimicrobials Working Group (AWG)
Subscribe to our Free Newsletters!